BridgeBio Oncology Therapeutics Overview

BridgeBio Oncology Therapeutics Target Price

See BridgeBio Oncology Therapeutics's analyst price targets ($19) vs the current share price.

Get informed when a big investor buys or sells

+ Follow

Share Price

$2.62

Average Target Price

$19.00

625.2% upside

3 analysts in the last 4 months

High: $22 | Low: $15

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

Date	Analyst	Price Target	Current Upside/Downside
2026-09-09	Raymond JamesSean McCutcheon	$22	739.7% upside
2026-09-09	Stifel Nicolaus	$15	472.5% upside
2026-09-09	Canaccord Genuity	$20	663.4% upside
2026-05-11	Canaccord GenuityJohn Newman	$23	777.9% upside
2026-02-10	Stifel NicolausLaura Prendergast	$23	777.9% upside
2026-01-09	Raymond James	$24	816% upside
2026-01-08	Morgan Stanley	$18	587% upside
2025-12-05	Morgan Stanley	$20	663.4% upside
2025-09-17	Leerink Partners	$25	854.2% upside
2025-09-15	H.C. WainwrightRobert Burns	$27	930.5% upside
2025-09-04	Oppenheimer	$23	777.9% upside
2025-08-15	Piper SandlerBiren Amin	$21	701.5% upside

BridgeBio Oncology Therapeutics (BBOT) FAQ

BridgeBio Oncology Therapeutics (BBOT) currently reports a target price of $19. Use the charts on this page to explore BridgeBio Oncology Therapeutics's target price history and peer comparisons.

Analysts' average 12-month price target for BridgeBio Oncology Therapeutics is $19, about 625.2% upside from the current share price of $2.62. That spread summarizes where covering analysts expect the stock could trade over the next year, not a guarantee. Review the individual firm targets on this page — a wide high-to-low range often means opinion is split.

Start with the current target price of $19, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for BridgeBio Oncology Therapeutics, and consider following BBOT for alerts when major investors trade the stock.